Wednesday, July 8, 2026

Patent intelligence · US

US 10376588

Etanercept formulations stabilized with combinations of sugars and polyols

granted A61KA61K38/17A61K38/1793A61K38/191
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 13
Applicant portfolio 73
Related coverage 1
Patent details — US 10376588

Quick answer

US 10376588 (Etanercept formulations stabilized with combinations of sugars and polyols) is held by Coherus BioSciences, Inc.. Status: granted. Granted Aug 13, 2019. Expires Aug 8, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K38/17, A61K38/1793, A61K38/191, A61K39/39591, A61K47/10

More from Coherus BioSciences, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11667702

    Stable aqueous formulations of aflibercept

    Coherus BioSciences, Inc. · Expires Jun 1, 2043

    granted
  2. US 11583584

    Stable protein compositions and methods of their use

    Coherus BioSciences, Inc. · Expires Feb 16, 2043

    granted
  3. US 11576971

    Method of filling a container with no headspace

    Coherus BioSciences, Inc. · Expires Feb 9, 2043

    granted
  4. US 11426446

    Stable aqueous formulations of aflibercept

    Coherus BioSciences, Inc. · Expires Aug 25, 2042

    granted
  5. US 11400072

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Coherus BioSciences, Inc. · Expires Jul 28, 2042

    granted
  6. US 11396540

    Methods for making recombinant proteins

    Coherus BioSciences, Inc. · Expires Jul 21, 2042

    granted
  7. US 11253508

    PPARy agonist for treatment of progressive supranuclear palsy

    Coherus BioSciences, Inc. · Expires Feb 17, 2042

    granted
  8. US 11229702

    High concentration formulations of adalimumab

    Coherus BioSciences, Inc. · Expires Jan 20, 2042

    granted

Related coverage

Frequently asked questions

What is US patent 10376588?

US 10376588 (Etanercept formulations stabilized with combinations of sugars and polyols) is held by Coherus BioSciences, Inc.. Status: granted. Granted Aug 13, 2019. Expires Aug 8, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10376588?

Coherus BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 73 pharmaceutical patents for this assignee.

When does US 10376588 expire?

Our index shows an expiration date of Aug 8, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.